<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389685</url>
  </required_header>
  <id_info>
    <org_study_id>16-02038</org_study_id>
    <nct_id>NCT03389685</nct_id>
  </id_info>
  <brief_title>Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury</brief_title>
  <official_title>Can Platelet Rich Plasma Reduce the Level of Pro-Inflammatory Synovial Fluid Biomarkers Following an Anterior Cruciate Ligament Tear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this single-center, double-blinded randomized control trial with prospective
      data collection is to assess the ability of platelet rich plasma (PRP) treatment to reduce
      the level of pro-inflammatory synovial fluid biomarkers following an acute anterior cruciate
      ligament (ACL) tear. The study will collect and analyze synovial fluid of patients presenting
      with an acute anterior cruciate ligament (ACL) tear with a second synovial fluid sampling at
      the time of surgery. It will compare synovial fluid biomarker levels between those receiving
      an intra-articular Platelet Rich Plasma (PRP) injection versus an intra-articular saline
      injection serving as a control. Post-operative clinical outcomes will also be assessed,
      including post-operative pain levels, incidence of post-operative knee stiffness and patient
      reported outcome scores.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>synovial fluid biomarker levels</measure>
    <time_frame>2 Days</time_frame>
    <description>The synovial fluid samples obtained at the two time points will be analyzed for the presence of 20 biomarkers using a multiplex bead assay (Milliplex®, Millipore, Billerica MA)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ACL - Anterior Cruciate Ligament Rupture</condition>
  <condition>ACL Injury</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Unmarked syringe with 5 ml of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Pure PRPII®, leukocyte-poor, platelet rich plasma</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>saline solution</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have suffered an acute ACL tear (initial presentation within 7 days of
             injury) with or without an associated meniscus injury

          -  Patient must undergo ACL reconstruction surgery

        Exclusion Criteria:

          -  Mentally impaired (e.g, Alzheimer's subjects, dementia, etc.)

          -  Younger than 18 years of age

          -  Patients who have a multiligamentous injury

          -  Patients with underlying inflammatory arthropathies

          -  Previous ACL injury and/or reconstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Strauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hien Pham</last_name>
    <phone>646 501 7223</phone>
    <email>hien.pham@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hien Pham</last_name>
      <phone>646-501-7223</phone>
      <email>hien.pham@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet Rich Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

